関連する実験動画
Updated: Sep 9, 2025
02:14
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
Published on: August 1, 2025
461
多発性胃潰瘍による胃腸出血を有する川崎病の乳児
Takeru Kanazawa1, Tomokazu Nakagami1, Jyoji Yoshizawa1
1Children's Medical Center, Showa Medical University Koto Toyosu Hospital Tokyo Japan.
Journal of general and family medicine
|September 4, 2025
まとめ
予防的な治療にもかかわらず,重度の胃腸出血,川崎病 (KD) の希少な合併症が発生しました. このケースは,特にステロイドやNSAIDを服用している患者に対して,出血を防ぐために慎重にモニタリングする必要性を強調しています.
科学分野:
- 小児関節病学
- 胃腸内科
- 組織性血管炎
背景:
- カワサキ病 (KD) は,子供における心疾患の主要な原因です.
- 胃腸 (GI) 症状はKDでは一般的ですが,重度の胃腸出血はまれな合併症です.
- 標準的なKD治療には,静脈内免疫グロブリン (IVIG),アスピリン,およびコルチコステロイドが含まれています.
研究 の 目的:
- カワサキ病の不完全な患者の重度の消化器内出血を報告する.
- 薬剤による副作用を含む,KD患者における胃腸出血の潜在的な原因を調査する.
- KDの管理における GIの警戒性の重要性を強調する.
主な方法:
- カワサキ病と診断された 11ヶ月の女性の症例報告
- 臨床表現の見直し,診断作業,治療コース
- 薬剤を含む重度の胃腸出血に寄与する要因の分析
主要な成果:
- 患者は複数の胃潰瘍と重度の消化器内出血を発症し,輸血が必要でした.
- H2受容体抗体による予防療法にもかかわらず出血が発生した.
- 特定された潜在的要因には,KDそのものと,コルチコステロイドとNSAIDの併用効果が含まれています.
結論:
- 胃腸出血は 川崎病の直接的な重篤な合併症である可能性があります
- コルチコステロイドとNSAIDは,KD患者の腸内出血のリスクを増加させる可能性があります.
- 胃腸疾患の合併症に対する 警戒的なモニタリングと 予防策に関するさらなる研究が KD の管理に不可欠です
関連する概念動画
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
308
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
308
01:28Esophageal Varices-II: Clinical Features and Management
133
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
133
01:17Gastritis-II: Pathophysiology
537
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
537
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595
01:24Esophageal Varices-I: Introduction
324
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
324
01:30Peptic Ulcer Disease I: Introduction
282
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
282